Evasion of Toll-like receptor 2 activation by staphylococcal superantigen-like protein 3

Journal of Molecular Medicine

Volumn 90, Issue 10, 2012, Pages 1109-1120

  Bardoel, B W ^a,b   Vos, R ^a   Bouman, T ^a   Aerts, P C ^a   Bestebroer, J ^a   Huizinga, E G ^c   Brondijk, T H C ^c   Van Strijp, J A G ^a   De Haas, C J C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Immune evasion; Innate immunity; Keywords toll like receptor 2; SSL3; Staphylococcal superantigen like protein 3; Staphylococcus aureus; TLR2 antagonist

Indexed keywords

AMINO ACID; BACTERIAL PROTEIN; INTERLEUKIN 8; LIGAND; PROTEIN STAPHYLOCOCCAL SUPERANTIGEN LIKE 3; SIALIC ACID; SUPERANTIGEN; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AMINO TERMINAL SEQUENCE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNE EVASION; INNATE IMMUNITY; MONOCYTE; MOUSE; MUTANT; NEUTROPHIL; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SEQUENCE HOMOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, BACTERIAL; ANTIGENS, CD; GLYCOSYLATION; HEK293 CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; INTERLEUKIN-8; MICE; MONOCYTES; NEUTROPHILS; PROTEIN BINDING; SIALIC ACIDS; STAPHYLOCOCCUS AUREUS; SUPERANTIGENS; TOLL-LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867332769     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-012-0926-8     Document Type: Article

References (43)

1. Arpaia N, Barton GM (2011) Toll-like receptors: key players in antiviral immunity. Curr Opin Virol 1:447-454
2. Bardoel BW, Strijp JA (2012) Molecular battle between host and bacterium: recognition in innate immunity. J Mol Recognit 24:1077-1086
3. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11:373-384
4. Chang ZL (2010) Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflamm Res 59:791-808
5. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987-995
6. Krutzik SR, Sieling PA, Modlin RL (2001) The role of Toll-like receptors in host defense against microbial infection. Curr Opin Immunol 13:104-108
7. Medzhitov R (2001) Toll-like receptors and innate immunity. Nat Rev Immunol 1:135-145
8. Zahringer U, Lindner B, Inamura S, Heine H, Alexander C (2008) TLR2 - promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology 213:205-224
9. Jin MS, Lee JO (2008) Structures of the toll-like receptor family and its ligand complexes. Immunity 29:182-191
10. Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, Lee H, Lee JO (2007) Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130:1071-1082
11. Schenk M, Belisle JT, Modlin RL (2009) TLR2 looks at lipoproteins. Immunity 31:847-849
12. Archer KA, Roy CR (2006) MyD88-dependent responses involving toll-like receptor 2 are important for protection and clearance of Legionella pneumophila in a mouse model of Legionnaires' disease. Infect Immun 74:3325-3333
13. Dickinson GS, Piccone H, Sun G, Lien E, Gatto L, Alugupalli KR (2010) Toll-like receptor 2 deficiency results in impaired antibody responses and septic shock during Borrelia hermsii infection. Infect Immun 78:4579-4588
14. Mancuso G, Midiri A, Beninati C, Biondo C, Galbo R, Akira S, Henneke P, Golenbock D, Teti G (2004) Dual role of TLR2 and myeloid differentiation factor 88 in a mouse model of invasive group B streptococcal disease. J Immunol 172:6324-6329
15. Takeuchi O, Hoshino K, Akira S (2000) Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 165:5392-5396
16. Stenzel W, Soltek S, Sanchez-Ruiz M, Akira S, Miletic H, Schluter D, Deckert M (2008) Both TLR2 and TLR4 are required for the effective immune response in Staphylococcus aureus-induced experimental murine brain abscess. Am J Pathol 172:132-145
17. Rooijakkers SH, van Kessel KP, van Strijp JA (2005) Staphylococcal innate immune evasion. Trends Microbiol 13:596-601
18. Lina G, Bohach GA, Nair SP, Hiramatsu K, Jouvin-Marche E, Mariuzza R (2004) Standard nomenclature for the superantigens expressed by Staphylococcus. J Infect Dis 189:2334-2336
19. Bestebroer J, Poppelier MJ, Ulfman LH, Lenting PJ, Denis CV, van Kessel KP, van Strijp JA, de Haas CJ (2007) Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neutrophil rolling. Blood 109:2936-2943
20. Walenkamp AM, Bestebroer J, Boer IG, Kruizinga R, Verheul HM, van Strijp JA, de Haas CJ (2010) Staphylococcal SSL5 binding to human leukemia cells inhibits cell adhesion to endothelial cells and platelets. Cell Oncol 32:1-10
21. Bestebroer J, van Kessel KP, Azouagh H, Walenkamp AM, Boer IG, Romijn RA, van Strijp JA, de Haas CJ (2009) Staphylococcal SSL5 inhibits leukocyte activation by chemokines and anaphylatoxins. Blood 113:328-337
22. de Haas CJ, Weeterings C, Vughs MM, de Groot PG, Van Strijp JA, Lisman T (2009) Staphylococcal superantigen-like 5 activates platelets and supports platelet adhesion under flow conditions, which involves glycoprotein Ibalpha and alpha IIb beta 3. J Thromb Haemost 7:1867-1874
23. Itoh S, Hamada E, Kamoshida G, Takeshita K, Oku T, Tsuji T (2010) Staphylococcal superantigen-like protein 5 inhibits matrix metalloproteinase 9 from human neutrophils. Infect Immun 78:3298-3305
24. Bestebroer J, Aerts PC, Rooijakkers SH, Pandey MK, Kohl J, van Strijp JA, de Haas CJ (2010) Functional basis for complement evasion by staphylococcal superantigen-like 7. Cell Microbiol 12:1506-1516
25. Walenkamp AM, Boer IG, Bestebroer J, Rozeveld D, Timmer-Bosscha H, Hemrika W, van Strijp JA, de Haas CJ (2009) Staphylococcal superantigen-like 10 inhibits CXCL12-induced human tumor cell migration. Neoplasia 11:333-344
26. Itoh S, Hamada E, Kamoshida G, Yokoyama R, Takii T, Onozaki K, Tsuji T (2010) Staphylococcal superantigen-like protein 10 (SSL10) binds to human immunoglobulin G (IgG) and inhibits complement activation via the classical pathway. Mol Immunol 47:932-938
27. Patel D, Wines BD, Langley RJ, Fraser JD (2010) Specificity of staphylococcal superantigen-like protein 10 toward the human IgG1 Fc domain. J Immunol 184:6283-6292
28. Baker HM, Basu I, Chung MC, Caradoc-Davies T, Fraser JD, Baker EN (2007) Crystal structures of the staphylococcal toxin SSL5 in complex with sialyl Lewis X reveal a conserved binding site that shares common features with viral and bacterial sialic acid binding proteins. J Mol Biol 374:1298-1308
29. Chung MC, Wines BD, Baker H, Langley RJ, Baker EN, Fraser JD (2007) The crystal structure of staphylococcal superantigen-like protein 11 in complex with sialyl Lewis X reveals the mechanism for cell binding and immune inhibition. Mol Microbiol 66:1342-1355
30. Bardoel BW, Hartsink D, Vughs MM, de Haas CJ, van Strijp JA, van Kessel KP (2012) Identification of an immunomodulating metalloprotease of Pseudomonas aeruginosa (IMPa). Cell Microbiol 14:902-913
31. Haas PJ, de Haas CJ, Kleibeuker W, Poppelier MJ, van Kessel KP, Kruijtzer JA, Liskamp RM, van Strijp JA (2004) N-terminal residues of the chemotaxis inhibitory protein of Staphylococcus aureus are essential for blocking formylated peptide receptor but not C5a receptor. J Immunol 173:5704-5711
32. Bardoel BW, van der Ent S, Pel MJ, Tommassen J, Pieterse CM, van Kessel KP, van Strijp JA (2011) Pseudomonas evades immune recognition of flagellin in both mammals and plants. PLoS Pathog 7:e1002206
33. Jongerius I, Kohl J, Pandey MK, Ruyken M, van Kessel KP, van Strijp JA, Rooijakkers SH (2007) Staphylococcal complement evasion by various convertase-blocking molecules. J Exp Med 204:2461-2471
34. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28:2731-2739
35. Pathak SK, Basu S, Basu KK, Banerjee A, Pathak S, Bhattacharyya A, Kaisho T, Kundu M, Basu J (2007) Direct extracellular interaction between the early secreted antigen ESAT-6 of Mycobacterium tuberculosis and TLR2 inhibits TLR signaling inmacrophages. Nat Immunol 8:610-618
36. Jimenez-Dalmaroni MJ, Xiao N, Corper AL, Verdino P, Ainge GD, Larsen DS, Painter GF, Rudd PM, Dwek RA, Hoebe K et al (2009) Soluble CD36 ectodomain binds negatively charged diacylglycerol ligands and acts as a co-receptor for TLR2. PLoS One 4:e7411
37. Stuart LM, Deng J, Silver JM, Takahashi K, Tseng AA, Hennessy EJ, Ezekowitz RA, Moore KJ (2005) Response to Staphylococcus aureus requires CD36-mediated phagocytosis triggered by the COOH-terminal cytoplasmic domain. J Cell Biol 170:477-485
38. Gerold G, Ajaj KA, Bienert M, Laws HJ, Zychlinsky A, de Diego JL (2008) A Toll-like receptor 2-integrin beta3 complex senses bacterial lipopeptides via vitronectin. Nat Immunol 9:761-768
39. Meng G, Rutz M, Schiemann M, Metzger J, Grabiec A, Schwandner R, Luppa PB, Ebel F, Busch DH, Bauer S et al (2004) Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest 113:1473-1481
40. Weber AN, Morse MA, Gay NJ (2004) Four N-linked glycosylation sites in human toll-like receptor 2 cooperate to direct efficient biosynthesis and secretion. J Biol Chem 279:34589-34594
41. Fraser JD, Proft T (2008) The bacterial superantigen and superantigen-like proteins. Immunol Rev 225:226-243
42. O'Neill LA, Bryant CE, Doyle SL (2009) Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 61:177-197
43. Benson MA, Lilo S, Wasserman GA, Thoendel M, Smith A, Horswill AR, Fraser J, Novick RP, Shopsin B, Torres VJ (2011) Staphylococcus aureus regulates the expression and production of the staphylococcal superantigen-like secreted proteins in a Rot-dependent manner. Mol Microbiol 81:659-675